Company Profile
Replimune Group Stock Price, News & Analysis
Company overview
Business overview
Replimune Group is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Replimune Group is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
Replimune Group follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, Replimune Group sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Why the stock is moving
REPL is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Replimune's catalysts are RP1 and RP2, where melanoma and combination-immunotherapy updates can quickly change whether the oncolytic-virus thesis still looks powerful. The next clinical step matters because the platform is still judged almost entirely on data.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Replimune Provides Update Following Type A Meeting with FDA
Source: Replimune Group
- 02
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
Source: Replimune Group
- 03
- 04
Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update
Source: Replimune Group
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.